Literature DB >> 35224429

Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease.

Kaleb Bogale1, Wesley Raup-Konsavage2, Shannon Dalessio3, Kent Vrana2, Matthew D Coates2,3.   

Abstract

For centuries, cannabis and its components have been used to manage a wide variety of symptoms associated with many illnesses. Gastrointestinal (GI) diseases are no exception in this regard. Individuals suffering from inflammatory bowel disease (IBD) are among those who have sought out the ameliorating properties of this plant. As legal limitations of its use have eased, interest has grown from both patients and their providers regarding the potential of cannabis to be used in the clinical setting. Similarly, a growing number of animal and human studies have been undertaken to evaluate the impact of cannabis and cannabinoid signaling elements on the natural history of IBD and its associated complications. There is little clinical evidence supporting the ability of cannabis or related products to treat the GI inflammation underlying these disorders. However, 1 recurring theme from both animal and human studies is that these agents have a significant impact on several IBD-related symptoms, including abdominal pain. In this review, we discuss the role of cannabis and cannabinoid signaling in visceral pain perception, what is currently known regarding the efficacy of cannabis and its derivatives for managing pain, related symptoms and inflammation in IBD, and what work remains to effectively utilize cannabis and its derivatives in the clinical setting.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Abdominal pain; Cannabinoids; Cannabis; Crohn's disease; Endocannabinoid system; Inflammatory bowel disease; Ulcerative colitis

Year:  2021        PMID: 35224429      PMCID: PMC8832240          DOI: 10.1159/000517425

Source DB:  PubMed          Journal:  Med Cannabis Cannabinoids        ISSN: 2504-3889


  127 in total

1.  Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug.

Authors:  F Ferrari; A Ottani; D Giuliani
Journal:  Pharmacol Biochem Behav       Date:  1999-01       Impact factor: 3.533

2.  Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium.

Authors:  Edward S Kimball; Craig R Schneider; Nathaniel H Wallace; Pamela J Hornby
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-03-30       Impact factor: 4.052

3.  Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.

Authors:  David J Rog; Turo J Nurmikko; Tim Friede; Carolyn A Young
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

4.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 5.  The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.

Authors:  Zubair Malik; Daniel Baik; Ron Schey
Journal:  Curr Gastroenterol Rep       Date:  2015-02

6.  The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease.

Authors:  A Di Sabatino; N Battista; P Biancheri; C Rapino; L Rovedatti; G Astarita; A Vanoli; E Dainese; M Guerci; D Piomelli; S L F Pender; T T MacDonald; M Maccarrone; G R Corazza
Journal:  Mucosal Immunol       Date:  2011-04-06       Impact factor: 7.313

7.  Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.

Authors:  Niina Aaltonen; Juha R Savinainen; Casandra Riera Ribas; Jani Rönkkö; Anne Kuusisto; Jani Korhonen; Dina Navia-Paldanius; Jukka Häyrinen; Piia Takabe; Heikki Käsnänen; Tatu Pantsar; Tuomo Laitinen; Marko Lehtonen; Sanna Pasonen-Seppänen; Antti Poso; Tapio Nevalainen; Jarmo T Laitinen
Journal:  Chem Biol       Date:  2013-03-21

Review 8.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

Review 9.  The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity.

Authors:  Mireille Alhouayek; Giulio G Muccioli
Journal:  Trends Mol Med       Date:  2012-08-21       Impact factor: 11.951

10.  Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.

Authors:  R Capasso; F Borrelli; G Aviello; B Romano; C Scalisi; F Capasso; A A Izzo
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

View more
  1 in total

Review 1.  Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.

Authors:  Adam Shute; Dominique G Bihan; Ian A Lewis; Yasmin Nasser
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.